levodopa has been researched along with riluzole in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (11.11) | 18.2507 |
| 2000's | 10 (55.56) | 29.6817 |
| 2010's | 5 (27.78) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Djaldetti, R; Melamed, E; Merims, D; Ziv, I | 1 |
| Vale, S | 1 |
| Bezard, E; Bioulac, B; Boraud, T; Gross, CE; Stutzmann, JM | 1 |
| Bonastre, M; Chase, TN; Jimenez, A; Marin, C; Tolosa, E | 1 |
| Burkhardt, K; Ludolph, AC; Schwarz, J; Storch, A | 1 |
| Djaldetti, R; Melamed, E; Merims, D; Sherki, Y; Ziv, I | 1 |
| Hunter, C; Jankovic, J | 1 |
| Gilgun-Sherki, Y; Melamed, E; Offen, D; Ziv, I | 1 |
| Carta, M; Cenci, MA; Fisone, G; Håkansson, K; Lundblad, M; Usiello, A | 1 |
| Aksu, M; Bara-Jimenez, W; Chase, TN; Dimitrova, TD; Sherzai, A | 1 |
| Adeva-Bartolomé, T; Alonso-Navarro, H; Jiménez-Jiménez, FJ; Ruiz-Ezquerro, JJ | 1 |
| Barta, C; Glennon, J; Hengerer, B; Hildebrandt, T; Nespoli, E; Pagliaroli, L; Poelmans, G; Widomska, J | 1 |
| Aranyi, T; Barta, C; Devay, P; Fothi, A; Hengerer, B; Liko, I; Nespoli, E; Pagliaroli, L; Szeri, F; Veto, B | 1 |
2 trial(s) available for levodopa and riluzole
| Article | Year |
|---|---|
A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Dopamine Agonists; Double-Blind Method; Excitatory Amino Acid Antagonists; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Pilot Projects; Placebos; Riluzole; Severity of Illness Index; Time Factors | 2002 |
Glutamate release inhibition ineffective in levodopa-induced motor complications.
Topics: Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Glutamic Acid; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Riluzole; Treatment Outcome | 2006 |
16 other study(ies) available for levodopa and riluzole
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Riluzole for levodopa-induced dyskinesias in advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Riluzole; Treatment Outcome | 1999 |
Drug treatments of levodopa-induced dyskinesias.
Topics: Amantadine; Antiparkinson Agents; Dopamine Agents; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Humans; Levodopa; Patient Selection; Receptors, N-Methyl-D-Aspartate; Riluzole; Treatment Outcome | 1999 |
Effects of riluzole on the electrophysiological activity of pallidal neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkey.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Dopamine Agents; Electrophysiology; Female; Globus Pallidus; Levodopa; Macaca mulatta; Neurons; Neuroprotective Agents; Parkinson Disease, Secondary; Riluzole | 2000 |
Non-NMDA receptor-mediated mechanisms are involved in levodopa-induced motor response alterations in Parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Dextromethorphan; Excitatory Amino Acid Antagonists; Levodopa; Male; Motor Activity; Parkinsonian Disorders; Piperazines; Quinoxalines; Rats; Rats, Sprague-Dawley; Reaction Time; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Riluzole; Rotation | 2000 |
Protective effects of riluzole on dopamine neurons: involvement of oxidative stress and cellular energy metabolism.
Topics: 1-Methyl-4-phenylpyridinium; Adenosine Triphosphate; Animals; Cell Survival; Cells, Cultured; Chlorides; Dopamine; Dose-Response Relationship, Drug; Energy Metabolism; Ferric Compounds; Humans; Levodopa; Lipid Peroxidation; Neuroglia; Neurons; Oxidative Stress; Oxidopamine; Rats; Riluzole | 2000 |
The role of glutamatergic transmission in the pathogenesis of levodopa-induced dyskinesias. Potential therapeutic approaches.
Topics: Anticonvulsants; Antiparkinson Agents; Dopamine Agents; Dyskinesia, Drug-Induced; Excitatory Amino Acid Agents; Glutamic Acid; Humans; Levodopa; Parkinson Disease; Riluzole | 2001 |
Riluzole, an inhibitor of glutamatergic transmission, suppresses levodopa-induced rotations in 6-hydroxydopamine-lesioned rats.
Topics: Animals; Antiparkinson Agents; Apomorphine; Disease Models, Animal; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptors, Glutamate; Riluzole; Synaptic Transmission | 2003 |
Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
Topics: Adenosine A2 Receptor Agonists; Adrenergic Agents; Amantadine; Animals; Antiparkinson Agents; Basal Ganglia; Buspirone; Disease Models, Animal; Disease Progression; Dopamine Agonists; Drug Administration Schedule; Dyskinesia, Drug-Induced; Indoles; Levodopa; Male; Mice; Mice, Inbred C57BL; Oxidopamine; Parkinsonian Disorders; Purines; Receptor, Adenosine A2A; Receptors, Dopamine D2; Reproducibility of Results; Riluzole; Treatment Outcome | 2005 |
[Association between amytrophic lateral sclerosis and Parkinson's disease].
Topics: Aged; Amyotrophic Lateral Sclerosis; Antiparkinson Agents; Cabergoline; Carbidopa; Dopamine Agents; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Riluzole; Time Factors; Tomography, X-Ray Computed | 2007 |
Riluzole Attenuates L-DOPA-Induced Abnormal Involuntary Movements Through Decreasing CREB1 Activity: Insights from a Rat Model.
Topics: Animals; Cyclic AMP Response Element-Binding Protein; Disease Models, Animal; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Levodopa; Male; Oxidopamine; Protein Interaction Maps; Random Allocation; Rats; Rats, Wistar; Riluzole | 2019 |
Riluzole Administration to Rats with Levodopa-Induced Dyskinesia Leads to Loss of DNA Methylation in Neuronal Genes.
Topics: Animals; Corpus Striatum; DNA Methylation; Dyskinesia, Drug-Induced; Levodopa; Rats; Rats, Wistar; Riluzole | 2021 |